Search results for " area under the curve"

showing 2 items of 2 documents

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Vasoactive peptide urotensin II in plasma is associated with cerebral vasospasm after aneurysmal subarachnoid hemorrhage and constitutes a potential …

2019

National audience; OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in huma…

SAPS II = Simplified Acute Physiology Score IIMCA = middle cerebral arteryAUC = area under the curvesubarachnoid hemorrhage[SDV]Life Sciences [q-bio]ICU = intensive care unitUT = urotensin (receptor)vascular disordersintensive care unitUII = urotensin IIcardiovascular diseaseshumanmouseWFNS = World Federation of Neurosurgical SocietiesEVD = external ventricular drainageACA = anterior cerebral arteryurotensin IInervous system diseasesSAH = subarachnoid hemorrhageSE = standard errorROC = receiver operating characteristic[SDV] Life Sciences [q-bio]cerebral vasospasmVS = vasospasmDCI = delayed cerebral ischemiaCSF = cerebrospinal fluidIRB = institutional review boardmRS = modified Rankin ScaleIQR = interquartile range
researchProduct